New combo therapy offers hope for hard-to-treat breast cancer

This study is for people with HER2-negative breast cancer whose tumors did not shrink after initial chemotherapy. Researchers are testing whether adding an immunotherapy drug (toripalimab) and targeted radiation before and after surgery can improve outcomes. About 110 participants will receive either standard chemo, chemo plus toripalimab, or chemo plus toripalimab and radiation, followed by surgery and more immunotherapy. The goal is to see if these combinations lead to no cancer remaining at the time of surgery.